Home / Business and Economy / Bayer Stock Surges on Promising Cancer Drug Data
Bayer Stock Surges on Promising Cancer Drug Data
27 Oct
Summary
- Nubeqa significantly cut metastasis or death risk in prostate cancer patients.
- Bayer's stroke-prevention drug Asundexian gains first global marketing approval.
- Dual clinical and regulatory news propelled Bayer shares to lead German index.
Bayer's stock saw a notable rise of 3.2%, reaching 45.35, following significant weekend and early Monday morning pharmaceutical news. The company announced interim results from its Phase III DASL-HiCaP trial, indicating that Nubeqa, when used with hormone-deprivation therapy and radiation, reduced the risk of metastasis or death by 58% compared to a placebo. This finding offers substantial clinical validation for the prostate cancer treatment.
Further bolstering Bayer's position, its stroke-prevention compound Asundexian, developed to succeed the blockbuster Xarelto, secured its initial global marketing approval from Chinese regulators. This milestone is a crucial advancement for Bayer's cardiovascular drug portfolio. The positive developments contributed to Bayer leading the German DAX index, as the broader pharmaceutical sector also experienced gains with companies like Sanofi, Novartis, and Pfizer advancing.
